Clinical trial · no report yet · Phase 2
NCT06107686
A Study of YL202 in Selected Patients With Advanced Solid Tumors
- NCT06107686 ↗
- Recruiting
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 4 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Open-Label, Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of YL202 in Selected Patients With Advanced Solid Tumors
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- NSCLC; Breast Cancer; HNSCC; Locally Advanced or Metastatic Solid Tumors
- Interventions
- YL202 should be intravenously infused
- Arms
- Corhort A · Experimental
- Corhort B · Experimental
- Corhort C · Experimental
- Corhort D · Experimental
- Enrollment
- 200 (estimated)
- Primary outcomes
- ORR assessed according to RECIST v1.1
- Determination of the recommended dose of YL202 in the pivotal clinical study
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Start
- Dec 15, 2023
- Primary completion
- Nov 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06107686 · updated Nov 26, 2025